PON2 and chronic myelogenous leukemia, BCR-ABL1 positive: Here, we investigated PON2 expression in additional Bcr/Abl-positive CML cell lines, Lama84 and KCL22, either sensitive (S) or resistant (R) against Imatinib [31].